Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas

Alba Ariela Brandes, Elvira Scelzi, Paolo Zampieri, Alberto Rigon, Antonino Rotilio, Pietro Amista, Franco Berti, Mario V. Fiorentino

Research output: Contribution to journalArticle

Abstract

A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.

Original languageEnglish
Pages (from-to)364-367
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number4
DOIs
Publication statusPublished - Aug 1997

Fingerprint

Carmustine
Glioma
Interferons
Drug Therapy
Survival
Recycling
Radiation
Neoplasms

Keywords

  • BCNU
  • Central nervous system tumors
  • Chemotherapy
  • Cytoreductive surgery
  • Interferon

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas. / Brandes, Alba Ariela; Scelzi, Elvira; Zampieri, Paolo; Rigon, Alberto; Rotilio, Antonino; Amista, Pietro; Berti, Franco; Fiorentino, Mario V.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 4, 08.1997, p. 364-367.

Research output: Contribution to journalArticle

Brandes, Alba Ariela ; Scelzi, Elvira ; Zampieri, Paolo ; Rigon, Alberto ; Rotilio, Antonino ; Amista, Pietro ; Berti, Franco ; Fiorentino, Mario V. / Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1997 ; Vol. 20, No. 4. pp. 364-367.
@article{465fbfa09418407da3614babac0bcb8d,
title = "Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas",
abstract = "A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33{\%}; 95{\%} CI = 15-57) and stable disease in 6 (29{\%}; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.",
keywords = "BCNU, Central nervous system tumors, Chemotherapy, Cytoreductive surgery, Interferon",
author = "Brandes, {Alba Ariela} and Elvira Scelzi and Paolo Zampieri and Alberto Rigon and Antonino Rotilio and Pietro Amista and Franco Berti and Fiorentino, {Mario V.}",
year = "1997",
month = "8",
doi = "10.1097/00000421-199708000-00008",
language = "English",
volume = "20",
pages = "364--367",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas

AU - Brandes, Alba Ariela

AU - Scelzi, Elvira

AU - Zampieri, Paolo

AU - Rigon, Alberto

AU - Rotilio, Antonino

AU - Amista, Pietro

AU - Berti, Franco

AU - Fiorentino, Mario V.

PY - 1997/8

Y1 - 1997/8

N2 - A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.

AB - A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.

KW - BCNU

KW - Central nervous system tumors

KW - Chemotherapy

KW - Cytoreductive surgery

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=0030856633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030856633&partnerID=8YFLogxK

U2 - 10.1097/00000421-199708000-00008

DO - 10.1097/00000421-199708000-00008

M3 - Article

C2 - 9256890

AN - SCOPUS:0030856633

VL - 20

SP - 364

EP - 367

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -